专题：2025可持续全球领导者大会&首届绿色产业与可持续消费博览会 The 2025 Sustainable Global Leaders Conference took place from October 16 to 18 in the Expo Park, Huangpu District, Shanghai. The conference, co-hosted by the World Green Design Organization (WGDO) and Sina Group, is supported by the Beijing office of the International Financial Reporting Standards Foundation (IFRS Foundation) and organized by Sina Finance and the Beijing representative office of WGDO, with support from the Huangpu District Government. As the global cooperation partner of the conference, Shenenergy Group hosted a sub-forum focusing on the core theme of "Shanghai Action and Multidimensional Collaboration in Global Transformation," discussing topics such as "Creating a Sustainable Eastern Model," "Decoding the Sustainable Dynamics of Shanghai's Industrial Upgrading," and "Exploring New Growth Paradigms for Shanghai's Five Centers."

Fosun Pharma's Chairman Chen Yuqing attended the conference and delivered a keynote speech titled "Leading with Innovation, Steadily Expanding Globally." Chen emphasized that "innovative drugs require a decade of relentless effort and accumulation." Over the past decade, China's innovative drug industry has achieved significant qualitative leaps. As of 2024, the R&D share of innovative drugs in China has surged from 5% in the early years to 30%, approaching the 35% level in the United States. From an international collaboration perspective, the R&D numbers and commercial value of China's innovative drugs are witnessing dual breakthroughs in both quantity and quality. Currently, the number of innovative drugs under research in China accounts for about 30% globally, ranking second worldwide. In the first half of 2025, Chinese pharmaceutical companies achieved a record $60 billion in out-licensing (License-out) transactions for innovative drugs, significantly exceeding the total for the entire year of 2024. As a global healthcare industry group driven by innovation, Fosun Pharma invests approximately 5 billion RMB annually in R&D, making up nearly 17% of its total pharmaceutical revenue. The company has developed an innovation system encompassing independent research, collaborative development, licensing, fund incubation, and industrial investment, covering the entire R&D cycle from early-stage innovation to clinical phases. Currently, Fosun Pharma focuses on core therapeutic areas such as oncology and immune-inflammatory diseases, continuously investing in technical platforms for antibodies, ADCs, cell therapies, and small molecules. Since 2019, 12 innovative drugs have been launched, with 4 new products approved for market in the first half of this year, expanding and iterating its product pipeline.

Chen stated that "Leading with innovation and steadily expanding globally" is Fosun Pharma's strategic choice in practicing sustainable development and an essential pathway to support the construction of Shanghai's five centers. After over thirty years of development, Fosun Pharma has established an open innovation system and robust global operations, paving a high-quality and sustainable development path, emerging as a globally competitive healthcare group rooted in China and driven by innovation. In promoting the localization of global innovation, Fosun Pharma has transformed from a "distributor" to an "integrated R&D-manufacturing-sales" model. For example, the Da Vinci surgical robot has established the largest headquarters base in the Asia-Pacific region in Shanghai, operational since 2024, integrating Fosun's R&D and manufacturing system into the global supply chain; at the same time, it introduces innovative surgical devices in the field of central nervous system, such as the "Magnet Wave Knife," to provide innovative solutions for diseases like Parkinson's tremors. To address the challenges of original innovation, Fosun Pharma is pursuing a dual approach through industrial funds and research collaborations to stimulate innovative capacity. Five years ago, the Fosun Pharma-led Rehabilitation Capital New Drug Innovation Fund has incubated 10 cutting-edge projects involving stem cells, nucleic acid drugs, targeted conjugation drugs, and gene therapies. Recently, one of the enterprises incubated by this fund, focusing on innovative gene therapies for ophthalmology—Xingming Youjian—achieved a $400 million overseas licensing deal for its optogenetics pipeline UGX202, reflecting the global value recognition of this innovative pipeline. Additionally, Fosun Pharma collaborates with universities, high-level research hospitals, and global experts to strengthen target discovery and clinical protocol design. In terms of international expansion, Fosun Pharma began with artemisinin-based anti-malarial products and has cultivated the African market for nearly 20 years, supplying over 420 million injections of artemether to the global market, treating more than 84 million severe malaria patients, most of whom are children under five years old. Currently, Fosun Pharma is accelerating its presence in mainstream global markets while continuously enhancing its global operational capabilities, including establishing multiple R&D centers to realize global innovation and further refine the commercialization framework in various regulatory markets through self-construction and partnerships. In the U.S. market, Fosun Pharma's self-developed innovative biologic drug, the PD-1 monoclonal antibody Slulizumab, is undergoing a bridging trial in over 100 sites for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), with patient enrollment already completed. In the first half of this year, Fosun Pharma's overseas revenue reached nearly 5.5 billion RMB, accounting for 28% of its total revenue. As a company deeply rooted in China with a global perspective, Chen Yuqing believes that ESG leadership is a necessary choice for Fosun Pharma's development. In the realm of ESG, Fosun Pharma holds an AA rating from MSCI ESG, leading the industry, and is the only Chinese pharmaceutical company selected for the 2025 "Fortune" China ESG Impact List. Chen stated that Fosun Pharma remains committed to serving the public and giving back to society, supporting the construction of Shanghai's "five centers," promoting more innovative products to go global from China, and actively taking on a significant role in the development of China's healthcare industry.